Phase II study of cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097)
Suresh S. Ramalingam, Chandra P. Belani, Philip C. MacK, Everett E. Vokes, Jeffrey Longmate, Ramaswamy Govindan, Marianna Koczywas, S. Percy Ivy, David R. Gandara
Dive into the research topics of 'Phase II study of cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097)'. Together they form a unique fingerprint.